Neurocrine Biosciences
NBIX
330 hedge funds and large institutions have $6.44B invested in Neurocrine Biosciences in 2018 Q4 according to their latest regulatory filings, with 75 funds opening new positions, 110 increasing their positions, 111 reducing their positions, and 89 closing their positions.
75% more funds holding in top 10
Funds holding in top 10: 4 → 7 (+3)
54% more call options, than puts
Call options by funds: $82.5M | Put options by funds: $53.6M
2.23% more ownership
Funds ownership: 98% → 100.24% (+2.2%)
1% less repeat investments, than reductions
Existing positions increased: 110 | Existing positions reduced: 111
4% less funds holding
Funds holding: 345 → 330 (-15)
16% less first-time investments, than exits
New positions opened: 75 | Existing positions closed: 89
41% less capital invested
Capital invested by funds: $10.9B → $6.44B (-$4.46B)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital International Investors
Los Angeles,
California
|
+$313M |
| 2 |
Janus Henderson Group
London,
United Kingdom
|
+$158M |
| 3 |
CAM
Close Asset Management
London,
United Kingdom
|
+$99.6M |
| 4 |
Marshall Wace
London,
United Kingdom
|
+$60.1M |
| 5 |
CGT
Capital Guardian Trust
Los Angeles,
California
|
+$47.5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$180M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
-$103M |
| 3 |
1832 Asset Management
Toronto,
Ontario, Canada
|
-$79.2M |
| 4 |
Goldman Sachs
New York
|
-$70.2M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
-$45.3M |
NBIX Hedge Fund Activity: Q4 2018 in Review
330 of the 4,488 institutional investors tracked by Wall St. Rank reported a position in Neurocrine Biosciences (NBIX) for Q4 2018, worth a combined $6.44B — down 41% from $10.9B a quarter earlier.
Sellers outnumbered buyers: 89 funds closed out of NBIX and 75 opened new positions — a net loss of 14 holders — while 111 trimmed existing stakes and 110 added.
The largest buyer was Capital International Investors, adding an estimated $313M. The largest seller was T. Rowe Price Associates, cutting an estimated $180M.
- 330 institutional investors held Neurocrine Biosciences (NBIX) as of Q4 2018, down from 345 in Q3 2018.
- Funds reported $6.44B of Neurocrine Biosciences stock for Q4 2018, down 41% quarter-over-quarter.
- 75 funds opened new Neurocrine Biosciences positions in Q4 2018 and 89 closed out, a net change of -14 holders.
- The largest Neurocrine Biosciences buyer in Q4 2018 was Capital International Investors, an estimated $313M added.
- The largest Neurocrine Biosciences seller in Q4 2018 was T. Rowe Price Associates, an estimated $180M sold.
Based on aggregated 13F filings for Q4 2018.